Mylan launches generic Ultram painkiller
CANONSBURG – Mylan N.V. Monday announced the U.S. launch of tramadol hydrochloride extended-release tablets, the generic version of Valeant’s Ultram extended-release tablets.
Mylan received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for the product, which is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.
The tablets had U.S. sales of approximately $52.8 million for the 12 months ending Dec. 31, according to IMS Health.
Mylan is a global pharmaceutical company with a growing portfolio of more than 1,400 generic and branded pharmaceuticals, marketing its products in 165 countries and territories.